Oraqix is a drug owned by Dentsply Pharmaceutical Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 01, 2017. Details of Oraqix's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6031007 | Pharmaceutical composition with anaesthetic effect |
Apr, 2017
(7 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Oraqix is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Oraqix's family patents as well as insights into ongoing legal events on those patents.
Oraqix's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Oraqix's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 01, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Oraqix Generic API suppliers:
Lidocaine; Prilocaine is the generic name for the brand Oraqix. 7 different companies have already filed for the generic of Oraqix, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Oraqix's generic
About Oraqix
Oraqix is a drug owned by Dentsply Pharmaceutical Inc. It is used for managing pain and discomfort during periodontal scaling and root planning procedures. Oraqix uses Lidocaine; Prilocaine as an active ingredient. Oraqix was launched by Dentsply Pharm in 2003.
Approval Date:
Oraqix was approved by FDA for market use on 19 December, 2003.
Active Ingredient:
Oraqix uses Lidocaine; Prilocaine as the active ingredient. Check out other Drugs and Companies using Lidocaine; Prilocaine ingredient
Treatment:
Oraqix is used for managing pain and discomfort during periodontal scaling and root planning procedures.
Dosage:
Oraqix is available in gel form for periodontal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2.5%;2.5% | GEL | Prescription | PERIODONTAL |